Evolus Q1 revenue rises 7% on product sales

Evolus

04/05/2026 21:24

Overview

US performance beauty firm's Q1 revenue rose 7% yr/yr, driven by Jeuveau and HA gel sales

Company posted second straight quarter of positive adjusted EBITDA, reflecting improved operating leverage

Evolus reaffirmed full-year 2026 guidance for double-digit revenue growth and positive adjusted EBITDA margin

Outlook

Evolus projects 2026 net revenue between $327 mln and $337 mln

Company expects 2026 adjusted gross profit margin of 65.5% to 67.0%

Evolus anticipates low- to mid-single digit adjusted EBITDA margin in 2026

Result Drivers

JEUVEAU DEMAND - Co said unit growth for Jeuveau across U.S. and international markets supported Q1 revenue

HA GEL CONTRIBUTION - Injectable hyaluronic acid gels contributed to expanding share of wallet and Q1 revenue

CUSTOMER ENGAGEMENT - Increased customer penetration, strong reorder behavior, and loyalty program expansion drove results

Company press release: ID:nBw5Shkp1a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Product Revenue
$72.75 mln
Q1 Net Income
-$10.67 mln
Q1 Gross Margin
66.90%
Q1 Adjusted Gross Margin
68.00%
Q1 Gross Profit
$48.90 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Evolus Inc is $14.00, about 162.7% above its May 1 closing price of $5.33

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)